A PYMNTS Company

European Commission ends probe of AstraZeneca and Nycomed

By  |  March 2, 2012

The European Commission has ended its investigation of AstraZeneca and Nycomed. The Commission had launched unannounced investigations at premises of several pharmaceutical companies on November 30, 2010. Its probe centered around possible individual or joint plans to delay generics, in violation of Articles 101 and 102 of the TFEU.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Source: EC Press Release

     

    Related content: Whistling Past the Graveyard: The Problem with the Per Se Legality Treatment of Pay-For-Delay Settlements (Michael Kades, U.S. Federal Trade Commission)